Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD44 siRNA
- Development stage
- Unknown
- Lead developer
- Dharmacon
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Parenteral
01
Overview
anti-CD44 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of CD44, a cell-surface glycoprotein and receptor for hyaluronic acid that is widely implicated in cell adhesion, migration, and cancer stem cell-like phenotypes. In preclinical research, anti-CD44 siRNA is used to investigate the role of CD44 in tumor metastasis, cell proliferation, and chemoresistance across various cancer models, including breast cancer, glioblastoma, and pancreatic cancer. By silencing CD44 expression, it disrupts homophilic interactions and downstream signaling pathways, thereby reducing cell migration and promoting apoptosis.
- Other names
- CD44 siRNACD-44 siRNACD 44 siRNAsiRNA against CD44small interfering RNA targeting CD44
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on anti-CD44 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD44 siRNA.